Share

January 03, 2017; 88 (1) Editorial

A gestational dose of vitamin D per day keeps the MS doctor away

Ruth Ann Marrie, Martin Daumer
First published November 30, 2016, DOI: https://doi.org/10.1212/WNL.0000000000003469
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
185

Share

Article Information

vol. 88 no. 1 13-14
DOI: 
https://doi.org/10.1212/WNL.0000000000003469
PubMed: 
27903816
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published November 30, 2016.

Article Versions

Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Ruth Ann Marrie, MD, PhD and
    2. Martin Daumer, PhD
  1. Ruth Ann Marrie, MD, PhD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Editorial Board Multiple Sclerosis Journal, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received support as site Principal Investigator for clinical trials from Sanofi- Aventis (2007-2015)

    Research Support, Government Entities:

    1. Received support as principal investigator from the Canadian Institutes of Health Research (2010-2019), and Research Manitoba (2014-2019).

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Received support as principal investigator from Multiple Sclerosis Society of Canada (2009-2016) and the National Multiple Sclerosis Society (2013-2017), and as co-principal investigator from Multiple Sclerosis Scientific Foundation (2009-2018). Received support from Consortium of Multiple Sclerosis Centers (2004-2009, 2011-2014). Rx & D Health Research Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Martin Daumer, PhD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1)MedNous, Editorial Board, 2008 - present

    Patents:

    1. (1)Apparatus for measuring activity, Co-originator: M. Scholz, Trium Analysis Online GmbH, Patent No.: US 7,640,804 B2. January 5, 2010 [no income] (2)Method and device for detecting a movement pattern, Trium Analysis Online GmbH, Patent application: 10 2007 044 705.3-35. September 18, 2007 [no income] (3)Device and method to measure the activity of a person, Co-originator: M. Scholz, German Patent application: 10 2005 019 924.0, April 27, 2005 [no income] (4)Device and method to determine the fetal heart rate from ultrasound signals, Co-originator: C. Lederer, German Patent 103 45 717.8-35, December 8, 2005 [no income] (5)Method and device for detecting drifts, jumps and/or outliers of measurement values, German Patent application Nr. 198 39 047.5-35, Nov. 11, 2005, European Patent 1097439 (99939929.8-2215), March 3, 2004 [no income] (6)Method and device for detecting drifts, jumps and/or outliers of measurement values, US Patent 6,556,957, April 29, 2003 [no income] (7)System and method for patient monitoring, German Patent application 102.51.900.5, Co-originator: M. Scholz, J. Doerr, November 7, 2002 [no income]

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. Trium Analysis Online GmbH, managing director (50%)

    Consultancies:

    1. (1)University of Oxford, non-profit entity, statistical consulting (2)Imperial Collage London, non-profit entity, statistical consulting (3)University of Southampton, non-profit entity, statistical analysis (4)Charite, Berlin, non-profit entity, use of actibelt technology in space (5)Univ. Vienna, Greencoat Ltd, non-profit entity, use of actibelt technology in dogs (6)Biopartners, commercial, Consultancy in a Multiple Sclerosis clinical trial (7)Biogen, commercial, statistical analysis, tool validation for decision support system (8)Bayer Schering, commercial, use of actibelt technology in clinical trials (9)Roche, commercial, use of actibelt technology in clinical trials (10)Novartis, commercial, use of actibelt technology in clinical trials

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Althogh somewhat far fetched: my firm belief in the importance of objective measurements of physical activity as a key lifestyle factor in epidemiological studies and clinical trials is linked to the technology platform actibelt that I have developed.

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1)EU-FP7, EASY IMP, 2013-2016 (2)EU-FP7, FP7-223865, 2008-2012 (3)EU-FP7, 215820-2, 2008-2012 (4)BMBF, KKNMS, 01Gl0904, 2009-2012 (5)BMBF, KKNMS, 01Gl0920, 2009-2012 (6)BWiMi, KF0564001 KF7, 2008-2009

    Research Support, Academic Entities:

    1. (1) Technical University of Munich, for Lecture “Clinical Applicatoins of Computational Medicine”

    Research Support, Foundations and Societies:

    1. (1)Hertie Foundation, 1.01.1/07/015, 2007-2009 (2)Porticus Foundation, 2006-2010

    Stock/Stock Options/Board of Directors Compensation:

    1. MD is managing director of Trium Analysis Online GmbH (50%)

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. MD is managing director of Trium Analysis Online GmbH (50%).

    Legal Proceedings:

    1. NONE

  1. From the Departments of Internal Medicine and Community Health Sciences (R.A.M.), University of Manitoba, Winnipeg, Canada; and Sylvia Lawry Centre for Multiple Sclerosis Research eV–The Human Motion Institute (M.D.), Munich, Germany.
  1. Correspondence to Dr. Marrie: rmarrie{at}exchange.hsc.mb.ca
View Full Text

Article usage

Article usage: November 2016 to April 2022

AbstractFullPdfSource
Nov 201614602Highwire
Dec 201612192672Highwire
Jan 201716012744Highwire
Feb 2017121119Highwire
Mar 201782118Highwire
Apr 20175854Highwire
May 20176567Highwire
Jun 20174202Highwire
Jul 20172720Highwire
Aug 20173901Highwire
Sep 20173921Highwire
Oct 20173712Highwire
Nov 20174612Highwire
Dec 20174032Highwire
Jan 20182421Highwire
Feb 20181700Highwire
Mar 20183852Highwire
Apr 20182221Highwire
May 20182602Highwire
Jun 20182700Highwire
Jul 20181700Highwire
Aug 20185353Highwire
Sep 20185701Highwire
Oct 20185800Highwire
Nov 20185311Highwire
Dec 20185311Highwire
Jan 20192901Highwire
Feb 20193621Highwire
Mar 20194101Highwire
Apr 20192811Highwire
May 20193700Highwire
Jun 20193211Highwire
Jul 20193800Highwire
Aug 20194010Highwire
Sep 20194501Highwire
Oct 20194411Highwire
Nov 20196000Highwire
Dec 20194701Highwire
Jan 20204111Highwire
Feb 20206010Highwire
Mar 20202811Highwire
Apr 20204911Highwire
May 20206200Highwire
Jun 20206131Highwire
Jul 20205400Highwire
Aug 20205500Highwire
Sep 20205900Highwire
Oct 20207320Highwire
Nov 20204421Highwire
Dec 20203501Highwire
Jan 20211700Highwire
Feb 20215400Highwire
Mar 20213810Highwire
Apr 20214100Highwire
May 20212801Highwire
Jun 20213700Highwire
Jul 20213800Highwire
Aug 20213300Highwire
Sep 20211500Highwire
Oct 20212600Highwire
Nov 20211611Highwire
Dec 20211400Highwire
Jan 20221221Highwire
Feb 20221000Highwire
Mar 20222210Highwire
Apr 20222600Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me